

Appendix: Tables

| | | |
|----|--|----|
| 1. | Sales January to September 2015 and 2014 | 2 |
| 2. | Quarterly sales and constant exchange rate sales growth by Division in 2015 and 2014..... | 3 |
| 3. | Pharmaceuticals Division | 4 |
| 4. | Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD September 2015 vs. YTD September 2014..... | 5 |
| 5. | Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth..... | 6 |
| 6. | Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States..... | 7 |
| 7. | Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe..... | 8 |
| 8. | Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan..... | 9 |
| 9. | Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International**..... | 10 |

1. Sales January to September 2015 and 2014

| CHF millions | Nine months ended 30 September | | % change | |
|--------------------------|-----------------------------------|--------|----------|--------|
| | 2015 | 2014 | At CER* | In CHF |
| Pharmaceuticals Division | 27,690 | 26,965 | 6 | 3 |
| United States | 13,047 | 11,528 | 7 | 13 |
| Europe | 6,476 | 7,070 | 3 | -8 |
| Japan | 2,341 | 2,406 | 8 | -3 |
| International** | 5,826 | 5,961 | 6 | -2 |
| Diagnostics Division | 7,835 | 7,792 | 6 | 1 |
| Roche Group | 35,525 | 34,757 | 6 | 2 |

* Constant exchange rates versus YTD September 2014

** Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

2. Quarterly sales and constant exchange rate sales growth by Division in 2015 and 2014

| CHF millions | Q3 2014 | % change vs. Q3 2013 | Q4 2014 | % change vs. Q4 2013 | Q1 2015 | % change vs. Q1 2014 | Q2 2015 | % change vs. Q2 2014 | Q3 2015 | % change vs. Q3 2014 |
|--------------------------|----------------|-------------------------------------|----------------|-------------------------------------|----------------|-------------------------------------|----------------|-------------------------------------|----------------|-------------------------------------|
| Pharmaceuticals Division | 9,131 | 4 | 9,731 | 5 | 9,322 | 4 | 9,028 | 7 | 9,340 | 6 |
| United States | 3,956 | 4 | 4,294 | 10 | 4,392 | 6 | 4,194 | 7 | 4,461 | 7 |
| Europe | 2,295 | 1 | 2,352 | 4 | 2,178 | 1 | 2,113 | 3 | 2,185 | 6 |
| Japan | 825 | 8 | 895 | 5 | 763 | -2 | 777 | 18 | 801 | 8 |
| International* | 2,055 | 6 | 2,190 | 0 | 1,989 | 9 | 1,944 | 5 | 1,893 | 4 |
| Diagnostics Division | 2,652 | 7 | 2,974 | 7 | 2,511 | 6 | 2,724 | 7 | 2,600 | 4 |
| Roche Group | 11,783 | 5 | 12,705 | 6 | 11,833 | 5 | 11,752 | 7 | 11,940 | 6 |

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

3. Pharmaceuticals Division

| Top-selling pharmaceuticals and recent new launches January - September 2015 | Total | | United States | | Europe | | Japan | | International** | |
|--|-------|-----|---------------|-----|--------|-----|-------|----|-----------------|-----|
| | CHF m | %* | CHF m | %* | CHF m | %* | CHF m | %* | CHF m | %* |
| MabThera/Rituxan | 5,268 | 5 | 2,822 | 7 | 1,350 | 0 | 166 | 11 | 930 | 7 |
| Avastin | 4,968 | 9 | 2,286 | 8 | 1,348 | 4 | 538 | 15 | 796 | 18 |
| Herceptin | 4,879 | 10 | 1,785 | 16 | 1,500 | 0 | 190 | 5 | 1,404 | 15 |
| Lucentis | 1,142 | -15 | 1,142 | -15 | - | - | - | - | - | - |
| Actemra/RoActemra | 1,042 | 22 | 397 | 28 | 344 | 21 | 160 | 14 | 141 | 23 |
| Perjeta | 1,035 | 66 | 587 | 46 | 302 | 117 | 61 | 17 | 85 | 145 |
| Xolair | 932 | 25 | 932 | 25 | - | - | - | - | - | - |
| Tarceva | 894 | -7 | 478 | -7 | 168 | -17 | 68 | 2 | 180 | 2 |
| Activase/TNKase | 676 | 15 | 644 | 16 | - | - | - | - | 32 | -8 |
| CellCept | 582 | -4 | 147 | -10 | 131 | -10 | 40 | 5 | 264 | 1 |

| Recent new launches | | | | | | | | | | |
|---------------------|-----|-----|-----|-----|-----|-----|----|-----|----|-----|
| Kadcyla | 558 | 57 | 229 | 1 | 235 | 137 | 42 | 122 | 52 | 134 |
| Esbriet | 386 | - | 262 | - | 106 | - | - | - | 18 | - |
| Zelboraf | 158 | -25 | 32 | -43 | 92 | -28 | 3 | - | 31 | 13 |
| Erivedge | 118 | 30 | 83 | 38 | 26 | 1 | - | - | 9 | 119 |
| Gazyva/Gazyvaro | 91 | 182 | 55 | 71 | 15 | *** | - | - | 21 | *** |

* Constant exchange rates versus YTD September 2014

** Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

*** Over 500%

4. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD September 2015 vs. YTD September 2014

| CHF millions | Total | | United States | | Europe | | Japan | | International** | |
|--------------------|-------|-----|---------------|-----|--------|-----|-------|-----|-----------------|-----|
| | CHF m | %* | CHF m | %* | CHF m | %* | CHF m | %* | CHF m | %* |
| MabThera/Rituxan | 5,268 | 5 | 2,822 | 7 | 1,350 | 0 | 166 | 11 | 930 | 7 |
| Avastin | 4,968 | 9 | 2,286 | 8 | 1,348 | 4 | 538 | 15 | 796 | 18 |
| Herceptin | 4,879 | 10 | 1,785 | 16 | 1,500 | 0 | 190 | 5 | 1,404 | 15 |
| Lucentis | 1,142 | -15 | 1,142 | -15 | - | - | - | - | - | - |
| Actemra/RoActemra | 1,042 | 22 | 397 | 28 | 344 | 21 | 160 | 14 | 141 | 23 |
| Perjeta | 1,035 | 66 | 587 | 46 | 302 | 117 | 61 | 17 | 85 | 145 |
| Xolair | 932 | 25 | 932 | 25 | - | - | - | - | - | - |
| Tarceva | 894 | -7 | 478 | -7 | 168 | -17 | 68 | 2 | 180 | 2 |
| Activase/TNKase | 676 | 15 | 644 | 16 | - | - | - | - | 32 | -8 |
| CellCept | 582 | -4 | 147 | -10 | 131 | -10 | 40 | 5 | 264 | 1 |
| Kadcyla | 558 | 57 | 229 | 1 | 235 | 137 | 42 | 122 | 52 | 134 |
| Tamiflu | 535 | 16 | 412 | 54 | 13 | -81 | 53 | -6 | 57 | -3 |
| Pulmozyme | 472 | 11 | 326 | 9 | 86 | 4 | - | - | 60 | 32 |
| Pegasys | 405 | -48 | 42 | -76 | 79 | -54 | 13 | -70 | 271 | -30 |
| Esbriet | 386 | - | 262 | - | 106 | - | - | - | 18 | - |
| Xeloda | 384 | -36 | 43 | -76 | 32 | -52 | 64 | 6 | 245 | -19 |
| Mircera | 369 | 29 | - | - | 65 | -3 | 135 | 4 | 169 | 102 |
| NeoRecormon/Epogin | 272 | -12 | - | - | 115 | -10 | 35 | -11 | 122 | -15 |
| Valcyte/Cymevene | 270 | -47 | 56 | -82 | 116 | -4 | - | - | 98 | -5 |
| Rocephin | 206 | 4 | - | - | 28 | 0 | 22 | -3 | 156 | 6 |

* At constant exchange rates versus YTD September 2014

**Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

| CHF millions | Q3 2014 | % change vs. Q3 2013 | Q4 2014 | % change vs. Q4 2013 | Q1 2015 | % change vs. Q1 2014 | Q2 2015 | % change vs. Q2 2014 | Q3 2015 | % change vs. Q3 2014 |
|--------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|
| MabThera/Rituxan | 1,764 | 1 | 1,776 | -1 | 1,744 | 5 | 1,752 | 6 | 1,772 | 4 |
| Avastin | 1,652 | 6 | 1,668 | 7 | 1,619 | 6 | 1,644 | 13 | 1,705 | 8 |
| Herceptin | 1,597 | 9 | 1,596 | 7 | 1,652 | 12 | 1,613 | 10 | 1,614 | 7 |
| Lucentis | 432 | 2 | 441 | -5 | 394 | -9 | 375 | -16 | 373 | -18 |
| Actemra/RoActemra | 329 | 28 | 327 | 20 | 334 | 27 | 341 | 23 | 367 | 18 |
| Perjeta | 245 | 227 | 285 | 103 | 322 | 82 | 337 | 64 | 376 | 57 |
| Xolair | 264 | 33 | 274 | 29 | 281 | 28 | 312 | 27 | 339 | 21 |
| Tarceva | 320 | 0 | 321 | -2 | 295 | -3 | 307 | -10 | 292 | -7 |
| Activase/TNKase | 200 | 19 | 188 | 5 | 221 | 15 | 216 | 16 | 239 | 14 |
| CellCept | 210 | 0 | 188 | -4 | 197 | -7 | 191 | -1 | 194 | -4 |
| Kadcyla | 144 | 103 | 165 | 110 | 179 | 80 | 183 | 54 | 196 | 44 |
| Tamiflu | 80 | 121 | 507 | 129 | 376 | 6 | 41 | 61 | 118 | 46 |
| Pulmozyme | 149 | 13 | 170 | 4 | 146 | 4 | 160 | 15 | 166 | 14 |
| Pegasys | 229 | -22 | 204 | -29 | 168 | -39 | 117 | -58 | 120 | -45 |
| Esbriet | - | - | 44 | - | 88 | - | 141 | - | 157 | - |
| Xeloda | 149 | -61 | 153 | -56 | 136 | -53 | 124 | -29 | 124 | -11 |
| Mircera | 101 | -1 | 113 | 0 | 114 | 17 | 108 | 17 | 147 | 55 |
| NeoRecormon/Epogin | 111 | -12 | 118 | -1 | 93 | -10 | 89 | -19 | 90 | -8 |
| Valcyte/Cymevene | 192 | 19 | 181 | -9 | 100 | -41 | 87 | -47 | 83 | -52 |
| Rocephin | 72 | 18 | 78 | 14 | 79 | 18 | 63 | 0 | 64 | -8 |

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

| CHF millions | Q3 2014 | % change vs. Q3 2013 | Q4 2014 | % change vs. Q4 2013 | Q1 2015 | % change vs. Q1 2014 | Q2 2015 | % change vs. Q2 2014 | Q3 2015 | % change vs. Q3 2014 |
|--------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|
| MabThera/Rituxan | 859 | -4 | 851 | 5 | 937 | 10 | 938 | 7 | 947 | 4 |
| Avastin | 702 | 3 | 680 | 7 | 761 | 6 | 741 | 11 | 784 | 6 |
| Herceptin | 514 | 10 | 516 | 17 | 598 | 18 | 578 | 18 | 609 | 12 |
| Lucentis | 432 | 2 | 441 | -5 | 394 | -9 | 375 | -16 | 373 | -18 |
| Actemra/RoActemra | 112 | 39 | 114 | 31 | 124 | 35 | 129 | 30 | 144 | 21 |
| Perjeta | 143 | 202 | 160 | 86 | 187 | 60 | 192 | 43 | 208 | 37 |
| Xolair | 264 | 33 | 274 | 29 | 281 | 28 | 312 | 27 | 339 | 21 |
| Tarceva | 161 | 11 | 155 | 9 | 154 | 2 | 165 | -15 | 159 | -7 |
| Activase/TNKase | 187 | 18 | 176 | 4 | 210 | 16 | 206 | 18 | 228 | 15 |
| CellCept | 58 | 16 | 42 | -18 | 43 | -17 | 51 | 2 | 53 | -14 |
| Kadcyla | 70 | 3 | 69 | -7 | 78 | -1 | 72 | -2 | 79 | 6 |
| Tamiflu | 64 | 155 | 434 | 127 | 284 | 49 | 24 | 131 | 104 | 54 |
| Pulmozyme | 100 | 20 | 105 | 9 | 102 | 4 | 109 | 15 | 115 | 9 |
| Pegasys | 30 | -51 | 27 | -49 | 12 | -82 | 13 | -84 | 17 | -45 |
| Esbriet | - | - | 5 | - | 50 | - | 98 | - | 114 | - |
| Xeloda | 12 | -93 | 14 | -92 | 15 | -89 | 16 | -48 | 12 | 3 |
| Mircera | - | - | - | - | - | - | - | - | - | - |
| NeoRecormon/Epogin | - | - | - | - | - | - | - | - | - | - |
| Valcyte/Cymevene | 107 | 21 | 91 | -13 | 24 | -76 | 16 | -83 | 16 | -86 |
| Rocephin | - | - | -3 | - | - | - | - | - | - | - |

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

| CHF millions | Q3 2014 | % change vs. Q3 2013 | Q4 2014 | % change vs. Q4 2013 | Q1 2015 | % change vs. Q1 2014 | Q2 2015 | % change vs. Q2 2014 | Q3 2015 | % change vs. Q3 2014 |
|--------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|
| MabThera/Rituxan | 499 | 4 | 497 | 7 | 452 | 1 | 443 | -1 | 455 | 1 |
| Avastin | 489 | 1 | 486 | 3 | 456 | 3 | 435 | 4 | 457 | 5 |
| Herceptin | 558 | 4 | 538 | 2 | 508 | 0 | 490 | -1 | 502 | 0 |
| Lucentis | - | - | - | - | - | - | - | - | - | - |
| Actemra/RoActemra | 113 | 25 | 113 | 22 | 110 | 24 | 114 | 21 | 120 | 19 |
| Perjeta | 65 | 228 | 81 | 171 | 89 | 140 | 99 | 125 | 114 | 96 |
| Xolair | - | - | - | - | - | - | - | - | - | - |
| Tarceva | 75 | -9 | 74 | -9 | 58 | -15 | 56 | -16 | 54 | -20 |
| Activase/TNKase | - | - | - | - | - | - | - | - | - | - |
| CellCept | 54 | -6 | 52 | -11 | 44 | -10 | 43 | -9 | 44 | -10 |
| Kadcyla | 48 | * | 65 | * | 73 | 229 | 79 | 135 | 83 | 92 |
| Tamiflu | 1 | 49 | 1 | -93 | 11 | -83 | 1 | 478 | 1 | -65 |
| Pulmozyme | 30 | -5 | 30 | -2 | 29 | 2 | 28 | 2 | 29 | 8 |
| Pegasys | 50 | -38 | 42 | -46 | 31 | -55 | 24 | -58 | 24 | -45 |
| Esbriet | - | - | 36 | - | 32 | - | 37 | - | 37 | - |
| Xeloda | 18 | -76 | 16 | -77 | 13 | -59 | 9 | -53 | 10 | -41 |
| Mircera | 24 | -3 | 25 | -8 | 22 | -3 | 22 | -3 | 21 | -1 |
| NeoRecormon/Epogin | 47 | -15 | 44 | -10 | 39 | -10 | 38 | -11 | 38 | -9 |
| Valcyte/Cymevene | 43 | 22 | 47 | -9 | 40 | -2 | 37 | -8 | 39 | -1 |
| Rocephin | 7 | 17 | 13 | 7 | 15 | 14 | 8 | -8 | 5 | -15 |

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

| CHF millions | Q3 2014 | % change vs. Q3 2013 | Q4 2014 | % change vs. Q4 2013 | Q1 2015 | % change vs. Q1 2014 | Q2 2015 | % change vs. Q2 2014 | Q3 2015 | % change vs. Q3 2014 |
|--------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|
| MabThera/Rituxan | 61 | 5 | 61 | -4 | 52 | 1 | 55 | 28 | 59 | 7 |
| Avastin | 187 | 13 | 192 | 5 | 167 | 4 | 182 | 29 | 189 | 13 |
| Herceptin | 70 | 5 | 70 | -7 | 60 | -7 | 65 | 22 | 65 | 3 |
| Lucentis | - | - | - | - | - | - | - | - | - | - |
| Actemra/RoActemra | 56 | 21 | 58 | 11 | 49 | 1 | 54 | 28 | 57 | 13 |
| Perjeta | 21 | 375 | 21 | 32 | 18 | 12 | 21 | 21 | 22 | 18 |
| Xolair | - | - | - | - | - | - | - | - | - | - |
| Tarceva | 24 | 7 | 26 | -6 | 20 | -12 | 23 | 8 | 25 | 12 |
| Activase/TNKase | - | - | - | - | - | - | - | - | - | - |
| CellCept | 14 | -12 | 15 | -13 | 12 | -3 | 14 | 8 | 14 | 11 |
| Kadcyla | 12 | - | 14 | - | 12 | - | 15 | 81 | 15 | 39 |
| Tamiflu | 1 | 238 | 50 | 190 | 54 | -2 | -1 | -97 | - | - |
| Pulmozyme | - | - | - | - | - | - | - | - | - | - |
| Pegasys | 17 | 48 | 11 | -1 | 6 | -50 | 5 | -73 | 2 | -82 |
| Esbriet | - | - | - | - | - | - | - | - | - | - |
| Xeloda | 23 | -6 | 23 | -8 | 20 | -8 | 22 | 22 | 22 | 8 |
| Mircera | 50 | -2 | 51 | -11 | 40 | -14 | 47 | 23 | 48 | 6 |
| NeoRecormon/Epogin | 14 | -38 | 14 | -39 | 11 | -24 | 12 | 0 | 12 | -7 |
| Valcyte/Cymevene | - | - | - | - | - | - | - | - | - | - |
| Rocephin | 9 | -16 | 8 | -15 | 7 | -9 | 7 | 1 | 8 | -2 |

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International**

| CHF millions | Q3 2014 | % change vs. Q3 2013 | Q4 2014 | % change vs. Q4 2013 | Q1 2015 | % change vs. Q1 2014 | Q2 2015 | % change vs. Q2 2014 | Q3 2015 | % change vs. Q3 2014 |
|--------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|---------|----------------------------|
| MabThera/Rituxan | 345 | 9 | 367 | -17 | 303 | 2 | 316 | 13 | 311 | 5 |
| Avastin | 274 | 15 | 310 | 16 | 235 | 11 | 286 | 27 | 275 | 16 |
| Herceptin | 455 | 14 | 472 | 6 | 486 | 23 | 480 | 14 | 438 | 9 |
| Lucentis | - | - | - | - | - | - | - | - | - | - |
| Actemra/RoActemra | 48 | 21 | 42 | 6 | 51 | 55 | 44 | 8 | 46 | 15 |
| Perjeta | 16 | 341 | 23 | 177 | 28 | 222 | 25 | 112 | 32 | 125 |
| Xolair | - | - | - | - | - | - | - | - | - | - |
| Tarceva | 60 | -13 | 66 | -13 | 63 | 1 | 63 | 6 | 54 | -1 |
| Activase/TNKase | 13 | 27 | 12 | 12 | 11 | -2 | 10 | -10 | 11 | -11 |
| CellCept | 84 | -3 | 79 | 13 | 98 | -2 | 83 | 1 | 83 | 5 |
| Kadcyla | 14 | * | 17 | * | 16 | 333 | 17 | 131 | 19 | 74 |
| Tamiflu | 14 | 37 | 22 | 350 | 27 | -20 | 17 | 18 | 13 | 22 |
| Pulmozyme | 19 | 10 | 35 | -1 | 15 | 9 | 23 | 34 | 22 | 49 |
| Pegasys | 132 | -8 | 124 | -17 | 119 | -8 | 75 | -42 | 77 | -40 |
| Esbriet | - | - | 3 | - | 6 | - | 6 | - | 6 | - |
| Xeloda | 96 | -19 | 100 | -10 | 88 | -17 | 77 | -27 | 80 | -11 |
| Mircera | 27 | 1 | 37 | 30 | 52 | 99 | 39 | 24 | 78 | 206 |
| NeoRecormon/Epogin | 50 | 3 | 60 | 28 | 43 | -6 | 39 | -29 | 40 | -8 |
| Valcyte/Cymevene | 42 | 12 | 43 | -1 | 36 | 4 | 34 | -1 | 28 | -17 |
| Rocephin | 56 | 27 | 60 | 30 | 57 | 25 | 48 | 2 | 51 | -7 |

* Over 500%

** Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others